Cargando…
Response to “Tailored Use of Avacopan in a Case With Refractory Antineutrophil Cytoplasmic Autoantibody-Associated Renal Vasculitis and Concominant Complement System Activation”
Autores principales: | van Leeuwen, Jolijn R., Rabelink, Ton J., Teng, Y.K. Onno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939352/ https://www.ncbi.nlm.nih.gov/pubmed/36815117 http://dx.doi.org/10.1016/j.ekir.2022.11.014 |
Ejemplares similares
-
Tailored Use of Avacopan in a Case With Refractory Antineutrophil Cytoplasmic Antibody-Associated Renal Vasculitis and Concominant Complement System Activation
por: Hakroush, Samy, et al.
Publicado: (2022) -
Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: van Leeuwen, Jolijn R., et al.
Publicado: (2021) -
Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis
por: van Leeuwen, Jolijn R, et al.
Publicado: (2023) -
Avacopan as First-Line Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Steroid-Sparing Option
por: Gabilan, Charlotte, et al.
Publicado: (2022) -
Relevance of Combined Clinicopathologic Phenotype and Antineutrophil Cytoplasmic Autoantibody Serotype in the Diagnosis of Antineutrophil Cytoplasmic Autoantibody Vasculitis
por: Alba, Marco A., et al.
Publicado: (2022)